The present invention relates to recombinant self-assembling protein nanoparticles presenting an albumin-binding peptide at the surface. For the recombinant self-assembling protein nanoparticles according to the present invention, an albumin-binding peptide can reduce the immunogenicity of the recombinant self-assembling protein nanoparticles because the albumin-binding peptide is presented at the surface, and thus binds to an albumin protein present in vivo, and the albumin-binding peptide can also provide the cancer delivery function of the recombinant self-assembling protein nanoparticles because the albumin-binding peptide binds to albumin around cancer. Simultaneously, the binding of the albumin-binding peptide to albumin can significantly increase the in vivo residence time of the recombinant self-assembling protein nanoparticles, thus increasing the potential for use in various medical applications.

The present invention provides methods for treating an individual having bladder cancer, the methods comprising intravesical administration of an oncolytic virus and intravenously administering an anti-PD-1 antibody.

The present disclosure provides orthogonal chimeric cytokine receptor/orthogonal cytokine pairs and compositions and methods for modified immune cells or precursors thereof (e.g., modified T cells) comprising an orthogonal chimeric cytokine receptor (e.g., an oIL2R-IL9R chimeric receptor) and a chimeric antigen receptor (CAR) or a T cell receptor (TCR). The present disclosure further provides an oncolytic adenoviral vector comprising a nucleic acid sequence encoding an orthogonal cytokine (e.g., oIL2), as well as methods of using the modified cells and the vector for treating cancer in a subject in need thereof.

The present invention relates to an anti-tumor adenovirus that can evade the in-vivo immune system. The adenovirus having high ability to kill tumor of the present invention, by comprising a nucleic acid encoding a tumor albumin-binding domain, has significantly increased effects of infecting and killing tumor cells, exhibits an increase in binding with albumin to thereby evade in-vivo immune responses, leading to an increase in plasma half-life, is specifically delivered to cancer cells to produce systemic therapeutic effects, and can be topically delivered and has excellent selectivity, resulting in a remarkable effect in anti-tumor efficacy and, therefore, the adenovirus can be advantageously used as an anticancer composition or anticancer adjuvant in various types of cancer.

The present invention relates to a recombinant adenovirus with increased in-vivo safety, tissue specificity, and anticancer activities, and a use thereof. Specifically, the recombinant adenovirus comprising: a promoter of the liver tissue-specific phosphoenolpyruvate carboxykinase (PEPCK) gene; a trans-splicing ribozyme which is operably linked to the promoter and acts on a cancer-specific gene; a therapeutic gene or a reporter gene which is linked to the 3 exon of the ribozyme; and a serotype 35 fiber knob and a serotype 5 shaft, in which the orf4 gene is deleted from adenovirus E1, E3 and E4 orf1, shows remarkable in-vivo safety, high specificity for a target tissue, and remarkable anticancer effects, and thus can be useful for an anticancer drug or a cancer diagnostic agent as a gene delivery vector.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

The present application belongs to the technical field of gene therapy, and discloses a method for treating a tumor with a combination of an exogenous antigen and a therapeutic agent. The present application also discloses a composition including an exogenous antigen and a therapeutically effective amount of a therapeutic agent. With the exogenous antigen as a target, the therapeutic agent kills a tissue or cell carrying the exogenous antigen and does not act on any tissue or cell without the exogenous antigen, thereby specifically killing the tissue or cell, such as a tumor cell. Since the exogenous antigen can be expressed in different types of tumors in different individuals, the method of the present application is a broad-spectrum anti-tumor method.

The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.

The present description relates to an inhibitory RNA molecule, comprising an oligonucleotide that selectively knocks down expression a Nanog pseudogene expressed in many human cancers, a replicating viral vector capable of encoding such inhibitory RNA molecule, pharmaceutical compositions comprising said vector, and methods of treating cancer by administration of said pharmaceutical composition.